Show simple item record

dc.contributor.authorCorrie, P
dc.contributor.authorMarshall, A
dc.contributor.authorDunn, J
dc.contributor.authorMiddleton, M
dc.contributor.authorNathan, P
dc.contributor.authorGore, M
dc.contributor.authorDavidson, N
dc.contributor.authorNicholson, S
dc.contributor.authorKelly, C
dc.contributor.authorMarples, M
dc.contributor.authorDanson, S
dc.contributor.authorMarshall, E
dc.contributor.authorHouston, S
dc.contributor.authorBoard, R
dc.contributor.authorWaterston, A
dc.contributor.authorNobes, J
dc.contributor.authorHarries, M
dc.contributor.authorKumar, S
dc.contributor.authorYoung, G
dc.contributor.authorLorigan, Paul C
dc.date.accessioned2014-06-11T08:21:26Z
dc.date.available2014-06-11T08:21:26Z
dc.date.issued2014-05
dc.identifier.citationAdjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. 2014, 15 (6):620-30 Lancet Oncolen
dc.identifier.issn1474-5488
dc.identifier.pmid24745696
dc.identifier.doi10.1016/S1470-2045(14)70110-X
dc.identifier.urihttp://hdl.handle.net/10541/320613
dc.description.abstractBevacizumab, a monoclonal antibody that targets VEGF, has shown restricted activity in patients with advanced melanoma. We aimed to assess the role of bevacizumab as adjuvant treatment for patients with resected melanoma at high risk of recurrence. We report results from the preplanned interim analysis.
dc.language.isoenen
dc.rightsArchived with thanks to The lancet oncologyen
dc.titleAdjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.en
dc.typeArticleen
dc.contributor.departmentCambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK.en
dc.identifier.journalThe Lancet Oncologyen
html.description.abstractBevacizumab, a monoclonal antibody that targets VEGF, has shown restricted activity in patients with advanced melanoma. We aimed to assess the role of bevacizumab as adjuvant treatment for patients with resected melanoma at high risk of recurrence. We report results from the preplanned interim analysis.


Files in this item

This item appears in the following Collection(s)

Show simple item record